Palisade Bio Reports Second Quarter 2024 Financial Results and Provides Business Update | 08/13 08:05 | globenewswire.com |
Palisade Bio Selects Dose for Upcoming Phase 1 Clinical Study of PALI-2108 for Ulcerative Colitis | 08/08 08:00 | globenewswire.com |
Palisade Bio Participates in Virtual Investor “What this Means” Segment | 07/31 09:15 | globenewswire.com |
Palisade Bio Successfully Completes Microbiome Study Confirming Bacterial Enzymes for Local Bioactivation of Lead Product Candidate, PALI-2108 | 07/29 08:30 | globenewswire.com |
Palisade Bio Announces European Patent Office Issued a Decision to Grant Notice for Patent for Lead Product Candidate, PALI-2108 | 07/19 08:30 | globenewswire.com |
Palisade Bio Announces Successful Completion of First GMP Manufacturing of PALI-2108 Drug Substance and Engineering Batches of Drug Product | 07/11 08:00 | globenewswire.com |
Palisade Bio to Participate in the Virtual Investor Closing Bell Series | 06/24 09:00 | globenewswire.com |
Palisade Bio Provides Update on Advancement of its Strategic Collaboration with Strand Life Sciences | 06/21 08:15 | globenewswire.com |
Bears are Losing Control Over Palisade Bio (PALI), Here's Why It's a 'Buy' Now | 06/14 10:55 | zacks.com |
Palisade Bio Announces Notice of Allowance for Canadian Patent Covering Lead Product Candidate, PALI-2108 | 06/11 08:30 | globenewswire.com |